Abstracts tagged "Lung Disease and systemic sclerosis"

Abstract Number: 1715 • 2017 ACR/ARHP Annual Meeting
Mitochondrial DNA Mutations and Respiratory Chain Dysfunction in Lung Fibrosis of Systemic Sclerosis
Veronika K. Jaeger¹, Dirk Lebrecht^2,3, Andrew G. Nicholson^4,5, Athol U Wells^5,6, Suresh George⁷, Amiq Gazdhar⁸, Michael Tamm⁹, Nils Venhoff², Thomas Geiser⁸ and Ulrich A. Walker¹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ²Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ³Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁴Department of Histopathology, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom, ⁵National Heart and Lung Institute, Imperial College, London, United Kingdom, ⁶Interstitial Lung Disease Unit, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom, ⁷Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom, ⁸Department of Pulmonary Medicine, University Hospital Bern, Bern, Switzerland, ⁹Department of Pneumology, University Hospital Basel, Basel, Switzerland
Background/Purpose: Recent data have implemented reactive oxygen species (ROS) in the etiology of interstitial lung disease (ILD) in systemic sclerosis. Recent data from bleomycin mice…
Abstract Number: 678 • 2013 ACR/ARHP Annual Meeting
Quantifying Change In Pulmonary Function As a Prognostic Marker In Systemic Sclerosis-Related Interstitial Lung Disease
Owen Moore^1,2, Susanna Proudman³, Nicole Goh⁴, Tamera Corte⁵, Hannah Rouse⁶, Oliver Hennessy⁶, Vivek Thakkar⁷, Joanne Sahhar⁸, Janet E. Roddy⁹, Peter Youssef¹⁰, Eli Gabbay¹¹, Peter Nash¹², Jane Zochling¹³, Wendy Stevens¹⁴ and Mandana Nikpour¹⁵, ¹Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ²Rheumatology, Derriford Hospital, Plymouth, United Kingdom, ³Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Respiratory Medicine, Alfred Hospital, Melbourne, Australia, ⁵Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia, ⁶Department of Radiology, St. Vincent’s Hospital, Melbourne, Australia, ⁷St Vincent's Hospital, Melbourne, Australia, ⁸Rheumatology Unit, Monash Medical Centre, Clayton, Australia, ⁹Royal Perth Hospital, Perth, Australia, ¹⁰Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia, ¹¹Advanced Lung Disease Unit, Royal Perth Hospital, Perth, Australia, ¹²Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, ¹³Menzies Research Institute Tasmania, Hobart, Australia, ¹⁴Rheumatology, St Vincent's Hospital, Melbourne, Australia, ¹⁵Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc) but it is not severe or progressive in all patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].